Today, Quantbot Technologies LP Buys 12,855 Shares of Achillion Pharmaceuticals Inc. (ACHN)

Today, Quantbot Technologies LP Buys 12,855 Shares of Achillion Pharmaceuticals Inc. (ACHN)

Quantbot Technologies LP boosted its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 523.6% during the third quarter, Holdings Channel reports. The firm owned 15,310 shares of the biopharmaceutical company’s stock after buying an additional 12,855 shares during the period. Quantbot Technologies LP’s holdings in Achillion Pharmaceuticals were worth $124,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Achillion Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 8,454,713 shares of the biopharmaceutical company’s stock worth $65,947,000 after buying an additional 455,251 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Achillion Pharmaceuticals by 4.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,021,403 shares of the biopharmaceutical company’s stock worth $23,567,000 after buying an additional 136,258 shares during the period. American Century Companies Inc. increased its stake in shares of Achillion Pharmaceuticals by 7.2% in the second quarter. American Century Companies Inc. now owns 870,293 shares of the biopharmaceutical company’s stock worth $6,788,000 after buying an additional 58,521 shares during the period. BlackRock Investment Management LLC increased its stake in shares of Achillion Pharmaceuticals by 8.3% in the second quarter. BlackRock Investment Management LLC now owns 437,200 shares of the biopharmaceutical company’s stock worth $3,410,000 after buying an additional 33,620 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Achillion Pharmaceuticals by 7.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 419,370 shares of the biopharmaceutical company’s stock worth $3,272,000 after buying an additional 28,264 shares during the period. Institutional investors and hedge funds own 79.80% of the company’s stock.

Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded down 2.64% on Friday, reaching $4.43. 1,488,002 shares of the company’s stock were exchanged. The company’s market capitalization is $605.49 million. The firm’s 50 day moving average price is $5.81 and its 200-day moving average price is $7.87. Achillion Pharmaceuticals Inc. has a 12 month low of $3.78 and a 12 month high of $10.95.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. On average, equities analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.61) EPS for the current year.

A number of equities research analysts have recently commented on ACHN shares. Chardan Capital lifted their price target on shares of Achillion Pharmaceuticals from $4.00 to $5.00 and gave the stock a “sell” rating in a report on Friday, September 23rd. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Monday, November 7th. FBR & Co assumed coverage on shares of Achillion Pharmaceuticals in a report on Thursday, September 15th. They issued an “outperform” rating and a $16.00 target price for the company. Leerink Swann restated a “market perform” rating on shares of Achillion Pharmaceuticals in a report on Thursday, November 3rd. Finally, Jefferies Group restated a “hold” rating on shares of Achillion Pharmaceuticals in a report on Monday, September 26th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Achillion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $10.56.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Related posts

Leave a Comment